Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease.

Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin.

I schaemia modified albumin (IMA) is a recently developed biomarker of transient myocardial ischaemia. Circulating IMA is increased in patients with myocardial ischaemia, after percutaneous coronary intervention, 3 or in acute coronary syndromes. The test has recently been licensed by the US Food and Drug Administration for diagnostic use in suspected myocardial ischaemia. IMA is serum albumin ...

Mirror, mirror on the wall: the quest for the earliest marker of myocardial ischaemia.

In patients with acute ST-segment elevation myocardial infarction (STEMI), the diagnosis and immediate initiation of reperfusion therapy is based on the standard 12-lead ECG. Owing to the fact that cardiac markers appear in the blood a substantial time after the onset of symptoms, cardiac markers are neither helpful for early diagnosis of patients with STEMI nor should results be awaited before...

The Clinical Assessment of Ischaemia Modified Albumin and Troponin I in the Early Diagnosis of the Acute Coronary Syndrome Key Words: Acute Coronary Syndrome, Ischaemia modified albumin, Troponin I, Myocardial Ischaemia

The role of myocardial perfusion SPECT in short-term cardiac prognosis of end-stage renal disease

Introduction: One of the most important causes of death in patients with end-stage renal disease (ESRD) and even after kidney transplantation is cardiovascular diseases. Thus, cardiac evaluation is of utmost importance in the management of these patients especially during preoperative work up before renal transplantation. The aim of present study is to evaluate the role of myoc...

Exploring the role of dimethylarginine dimethylaminohydrolase-mediated reduction in tissue asymmetrical dimethylarginine levels in cardio-protective mechanism of ischaemic postconditioning in rats

Objective(s): Reperfusion of ischaemic myocardium results in reduced nitric oxide (NO) biosynthesis by endothelial nitric oxide synthase (eNOS) leading to endothelial dysfunction and subsequent tissue damage. Impaired NO biosynthesis may be partly due to increased levels of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of eNOS. As dimethylarginine dimet...